Chugai Pharmaceutical Co., Ltd. (CHGCF)
USD 43.0
(-7.53%)
USD 43.0
(-7.53%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 443.84 Billion JPY | -15.78% |
| 2022 | 531.22 Billion JPY | 26.65% |
| 2021 | 419.43 Billion JPY | 40.63% |
| 2020 | 298.25 Billion JPY | 43.38% |
| 2019 | 208.01 Billion JPY | 71.12% |
| 2018 | 121.56 Billion JPY | 25.14% |
| 2017 | 115.26 Billion JPY | 30.33% |
| 2016 | 93.25 Billion JPY | -14.67% |
| 2015 | 102.35 Billion JPY | 14.66% |
| 2014 | 92.74 Billion JPY | -1.01% |
| 2013 | 95.08 Billion JPY | -14.26% |
| 2012 | 89.75 Billion JPY | -27.47% |
| 2011 | 73.03 Billion JPY | -3.68% |
| 2010 | 83.67 Billion JPY | -12.82% |
| 2009 | 108.94 Billion JPY | 100.01% |
| 2008 | 83.31 Billion JPY | -10.95% |
| 2007 | 81.51 Billion JPY | 10.26% |
| 2006 | 77.03 Billion JPY | -25.39% |
| 2005 | 103.48 Billion JPY | 39.3% |
| 2004 | 72.19 Billion JPY | 19.6% |
| 2003 | 59.96 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 101.95 Billion JPY | -18.6% |
| 2024 Q2 | 160.11 Billion JPY | 58.52% |
| 2023 Q3 | 107.48 Billion JPY | -5.72% |
| 2023 Q4 | 115.93 Billion JPY | 7.87% |
| 2023 Q1 | 99.66 Billion JPY | -33.22% |
| 2023 FY | - JPY | -15.78% |
| 2023 Q2 | 114 Billion JPY | 14.39% |
| 2022 Q4 | 149.23 Billion JPY | 57.01% |
| 2022 Q2 | 100.72 Billion JPY | -45.91% |
| 2022 Q1 | 186.22 Billion JPY | 34.5% |
| 2022 FY | - JPY | 26.65% |
| 2022 Q3 | 95.04 Billion JPY | -5.64% |
| 2021 Q2 | 97.02 Billion JPY | 51.01% |
| 2021 Q1 | 64.25 Billion JPY | -12.07% |
| 2021 FY | - JPY | 40.63% |
| 2021 Q4 | 138.45 Billion JPY | 15.66% |
| 2021 Q3 | 119.7 Billion JPY | 23.37% |
| 2020 Q1 | 71.22 Billion JPY | 44.34% |
| 2020 Q3 | 85.59 Billion JPY | 25.21% |
| 2020 FY | - JPY | 43.38% |
| 2020 Q4 | 73.07 Billion JPY | -14.63% |
| 2020 Q2 | 68.36 Billion JPY | -4.02% |
| 2019 Q3 | 64.82 Billion JPY | 33.96% |
| 2019 Q2 | 48.39 Billion JPY | 6.45% |
| 2019 FY | - JPY | 71.12% |
| 2019 Q1 | 45.45 Billion JPY | 75.91% |
| 2019 Q4 | 49.34 Billion JPY | -23.88% |
| 2018 Q3 | 30.65 Billion JPY | 12.03% |
| 2018 Q4 | 25.84 Billion JPY | -15.71% |
| 2018 Q2 | 27.36 Billion JPY | -27.4% |
| 2018 Q1 | 37.69 Billion JPY | 69.81% |
| 2018 FY | - JPY | 25.14% |
| 2017 Q4 | 22.19 Billion JPY | -22.03% |
| 2017 Q2 | 21.47 Billion JPY | -14.09% |
| 2017 Q1 | 24.99 Billion JPY | 62.25% |
| 2017 FY | - JPY | 30.33% |
| 2017 Q3 | 28.47 Billion JPY | 32.57% |
| 2016 FY | - JPY | -14.67% |
| 2016 Q3 | 15.27 Billion JPY | -35.49% |
| 2016 Q2 | 23.68 Billion JPY | 17.42% |
| 2016 Q1 | 20.16 Billion JPY | 1.35% |
| 2016 Q4 | 15.4 Billion JPY | 0.85% |
| 2015 FY | - JPY | 14.66% |
| 2015 Q4 | 19.89 Billion JPY | -15.51% |
| 2015 Q3 | 23.55 Billion JPY | 3.79% |
| 2015 Q2 | 22.69 Billion JPY | 7.01% |
| 2015 Q1 | 21.2 Billion JPY | 26.65% |
| 2014 Q3 | 16.01 Billion JPY | 33.16% |
| 2014 Q4 | 16.74 Billion JPY | 4.53% |
| 2014 FY | - JPY | -1.01% |
| 2014 Q1 | 31.27 Billion JPY | 54.69% |
| 2014 Q2 | 12.02 Billion JPY | -61.54% |
| 2013 Q4 | 20.22 Billion JPY | 0.9% |
| 2013 Q3 | 20.04 Billion JPY | -14.57% |
| 2013 FY | - JPY | -14.26% |
| 2013 Q1 | 13.67 Billion JPY | 705.94% |
| 2013 Q2 | 23.45 Billion JPY | 71.52% |
| 2012 FY | - JPY | -27.47% |
| 2012 Q1 | 24.71 Billion JPY | -13.82% |
| 2012 Q4 | -2.25 Billion JPY | -109.6% |
| 2012 Q3 | 23.5 Billion JPY | -17.45% |
| 2012 Q2 | 28.46 Billion JPY | 15.18% |
| 2011 Q4 | 28.67 Billion JPY | -8.35% |
| 2011 FY | - JPY | -3.68% |
| 2011 Q3 | 31.29 Billion JPY | -9.59% |
| 2011 Q1 | 29.15 Billion JPY | -20.24% |
| 2011 Q2 | 34.61 Billion JPY | 18.71% |
| 2010 Q4 | 36.55 Billion JPY | 15.28% |
| 2010 Q2 | 33.8 Billion JPY | 28.03% |
| 2010 Q1 | 26.4 Billion JPY | -33.56% |
| 2010 FY | - JPY | -12.82% |
| 2010 Q3 | 31.7 Billion JPY | -6.2% |
| 2009 Q1 | 32.72 Billion JPY | 0.0% |
| 2009 Q3 | 38.36 Billion JPY | 5.01% |
| 2009 Q4 | 39.73 Billion JPY | 3.56% |
| 2009 FY | - JPY | 100.01% |
| 2009 Q2 | 36.53 Billion JPY | 11.65% |
| 2008 FY | - JPY | -10.95% |
| 2007 FY | - JPY | 10.26% |
| 2006 FY | - JPY | -25.39% |
| 2005 FY | - JPY | 39.3% |
| 2004 FY | - JPY | 19.6% |
| 2003 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AstraZeneca PLC | 13.28 Billion USD | -3239.803% |
| Bristol-Myers Squibb Company PFD CONV 2 | 19.41 Billion USD | -2185.873% |
| CSPC Pharmaceutical Group Limited | 1.14 Billion USD | -38560.525% |
| Clarus Therapeutics Holdings, Inc. | -39.7 Million USD | 1117964.249% |
| Novartis AG | 19.51 Billion USD | -2174.064% |
| PT Kalbe Farma Tbk. | 288.13 Million USD | -153942.385% |